- Home
- EAF vs VXRT Comparison
EAF vs VXRT Comparison
Compare EAF & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- VXRT
- Stock Information
- Founded
- EAF 1886
- VXRT N/A
- Country
- EAF United States
- VXRT United States
- Employees
- EAF N/A
- VXRT N/A
- Industry
- EAF Industrial Machinery/Components
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EAF Energy
- VXRT Health Care
- Exchange
- EAF Nasdaq
- VXRT Nasdaq
- Market Cap
- EAF 215.0M
- VXRT 200.3M
- IPO Year
- EAF 1995
- VXRT N/A
- Fundamental
- Price
- EAF $2.09
- VXRT $0.60
- Analyst Decision
- EAF Hold
- VXRT Strong Buy
- Analyst Count
- EAF 5
- VXRT 2
- Target Price
- EAF $1.75
- VXRT $3.00
- AVG Volume (30 Days)
- EAF 2.0M
- VXRT 1.6M
- Earning Date
- EAF 11-12-2024
- VXRT 11-13-2024
- Dividend Yield
- EAF N/A
- VXRT N/A
- EPS Growth
- EAF N/A
- VXRT N/A
- EPS
- EAF N/A
- VXRT N/A
- Revenue
- EAF $541,710,000.00
- VXRT $16,760,000.00
- Revenue This Year
- EAF N/A
- VXRT $67.95
- Revenue Next Year
- EAF $15.79
- VXRT N/A
- P/E Ratio
- EAF N/A
- VXRT N/A
- Revenue Growth
- EAF N/A
- VXRT 303.27
- 52 Week Low
- EAF $0.52
- VXRT $0.52
- 52 Week High
- EAF $2.76
- VXRT $1.54
- Technical
- Relative Strength Index (RSI)
- EAF 59.64
- VXRT 31.25
- Support Level
- EAF $2.01
- VXRT $0.67
- Resistance Level
- EAF $2.25
- VXRT $0.65
- Average True Range (ATR)
- EAF 0.22
- VXRT 0.05
- MACD
- EAF -0.02
- VXRT -0.01
- Stochastic Oscillator
- EAF 44.38
- VXRT 10.72
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two major product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.